|
|
|
|
|
|
Sponsors and Collaborators: |
Gynecologic Oncology Group National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00064025 |
RATIONALE: Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.
PURPOSE: This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix).
Condition | Intervention | Phase |
Endometrial Cancer |
Drug: medroxyprogesterone Procedure: conventional surgery Procedure: gene expression profiling Procedure: neoadjuvant therapy |
Phase II |
MedlinePlus related topics: | Cancer |
ChemIDplus related topics: | Medroxyprogesterone Medroxyprogesterone 17-acetate |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus |
Estimated Enrollment: | 60 |
Study Start Date: | October 2003 |
Estimated Primary Completion Date: | April 2004 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: This is a pilot, multicenter study.
Patients receive medroxyprogesterone intramuscularly once approximately 3 weeks before surgical hysterectomy.
A subset of 15 patients has tissue collected by pipelle biopsy or curettage at baseline, 72 hours after medroxyprogesterone therapy, and during surgery for gene expression arrays.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed primary endometrioid adenocarcinoma of the uterine corpus
Diagnosis by endometrial curettage or biopsy within the past 8 weeks
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
United States, Connecticut | |||||
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus | |||||
New Britain, Connecticut, United States, 06050 | |||||
Helen and Harry Gray Cancer Center at Hartford Hospital | |||||
Hartford, Connecticut, United States, 06102-5037 | |||||
United States, Illinois | |||||
University of Illinois Cancer Center | |||||
Chicago, Illinois, United States, 60612-7243 | |||||
United States, Iowa | |||||
Holden Comprehensive Cancer Center at University of Iowa | |||||
Iowa City, Iowa, United States, 52242-1002 | |||||
United States, Massachusetts | |||||
Massachusetts General Hospital | |||||
Boston, Massachusetts, United States, 02114 | |||||
United States, Nevada | |||||
Women's Cancer Center - Lake Mead | |||||
Las Vegas, Nevada, United States, 89102 | |||||
United States, Ohio | |||||
Case Comprehensive Cancer Center | |||||
Cleveland, Ohio, United States, 44106-5065 | |||||
Charles M. Barrett Cancer Center at University Hospital | |||||
Cincinnati, Ohio, United States, 45267 | |||||
United States, Oregon | |||||
Williamette Gynecologic Oncology PC | |||||
Portland, Oregon, United States, 97213 | |||||
United States, South Carolina | |||||
Hollings Cancer Center at Medical University of South Carolina | |||||
Charleston, South Carolina, United States, 29425 |
Gynecologic Oncology Group |
National Cancer Institute (NCI) |
Study Chair: | Richard Zaino, MD | Milton S. Hershey Medical Center |
Investigator: | Harrison G. Ball, MD | Levine Cancer Center at UMass Medical Center - Memorial Campus |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000306440, GOG-0211 |
First Received: | July 8, 2003 |
Last Updated: | September 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00064025 |
Health Authority: | United States: Federal Government |
|
|
|
|
|
|